Cargando…

PET imaging of α(v)β(3) integrin expression in tumours with (68)Ga-labelled mono-, di- and tetrameric RGD peptides

PURPOSE: Due to the restricted expression of α(v)β(3) in tumours, α(v)β(3) is considered a suitable receptor for tumour targeting. In this study the α(v)β(3)-binding characteristics of (68)Ga-labelled monomeric, dimeric and tetrameric RGD peptides were determined and compared with their (111)In-labe...

Descripción completa

Detalles Bibliográficos
Autores principales: Dijkgraaf, Ingrid, Yim, Cheng-Bin, Franssen, Gerben M., Schuit, Robert C., Luurtsema, Gert, Liu, Shuang, Oyen, Wim J. G., Boerman, Otto C.
Formato: Texto
Lenguaje:English
Publicado: Springer-Verlag 2010
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3005123/
https://www.ncbi.nlm.nih.gov/pubmed/20857099
http://dx.doi.org/10.1007/s00259-010-1615-x
_version_ 1782194070111649792
author Dijkgraaf, Ingrid
Yim, Cheng-Bin
Franssen, Gerben M.
Schuit, Robert C.
Luurtsema, Gert
Liu, Shuang
Oyen, Wim J. G.
Boerman, Otto C.
author_facet Dijkgraaf, Ingrid
Yim, Cheng-Bin
Franssen, Gerben M.
Schuit, Robert C.
Luurtsema, Gert
Liu, Shuang
Oyen, Wim J. G.
Boerman, Otto C.
author_sort Dijkgraaf, Ingrid
collection PubMed
description PURPOSE: Due to the restricted expression of α(v)β(3) in tumours, α(v)β(3) is considered a suitable receptor for tumour targeting. In this study the α(v)β(3)-binding characteristics of (68)Ga-labelled monomeric, dimeric and tetrameric RGD peptides were determined and compared with their (111)In-labelled counterparts. METHODS: A monomeric (E-c(RGDfK)), a dimeric (E-[c(RGDfK)](2)) and a tetrameric (E{E[c(RGDfK)](2)}(2)) RGD peptide were synthesised, conjugated with DOTA and radiolabelled with (68)Ga. In vitro α(v)β(3)-binding characteristics were determined in a competitive binding assay. In vivo α(v)β(3)-targeting characteristics of the compounds were assessed in mice with subcutaneously growing SK-RC-52 xenografts. In addition, microPET images were acquired using a microPET/CT scanner. RESULTS: The IC(50) values for the Ga(III)-labelled DOTA-E-c(RGDfK), DOTA-E-[c(RGDfK)](2) and DOTA-E{E[c(RGDfK)](2)}(2) were 23.9 ± 1.22, 8.99 ± 1.20 and 1.74 ± 1.18 nM, respectively, and were similar to those of the In(III)-labelled mono-, di- and tetrameric RGD peptides (26.6 ± 1.15, 3.34 ± 1.16 and 1.80 ± 1.37 nM, respectively). At 2 h post-injection, tumour uptake of the (68)Ga-labelled mono-, di- and tetrameric RGD peptides (3.30 ± 0.30, 5.24 ± 0.27 and 7.11 ± 0.67%ID/g, respectively) was comparable to that of their (111)In-labelled counterparts (2.70 ± 0.29, 5.61 ± 0.85 and 7.32 ± 2.45%ID/g, respectively). PET scans were in line with the biodistribution data. On all PET scans, the tumour could be clearly visualised. CONCLUSION: The integrin affinity and the tumour uptake followed the order of DOTA-tetramer > DOTA-dimer > DOTA-monomer. The (68)Ga-labelled tetrameric RGD peptide has excellent characteristics for imaging of α(v)β(3) expression with PET. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s00259-010-1615-x) contains supplementary material, which is available to authorized users.
format Text
id pubmed-3005123
institution National Center for Biotechnology Information
language English
publishDate 2010
publisher Springer-Verlag
record_format MEDLINE/PubMed
spelling pubmed-30051232011-01-19 PET imaging of α(v)β(3) integrin expression in tumours with (68)Ga-labelled mono-, di- and tetrameric RGD peptides Dijkgraaf, Ingrid Yim, Cheng-Bin Franssen, Gerben M. Schuit, Robert C. Luurtsema, Gert Liu, Shuang Oyen, Wim J. G. Boerman, Otto C. Eur J Nucl Med Mol Imaging Original Article PURPOSE: Due to the restricted expression of α(v)β(3) in tumours, α(v)β(3) is considered a suitable receptor for tumour targeting. In this study the α(v)β(3)-binding characteristics of (68)Ga-labelled monomeric, dimeric and tetrameric RGD peptides were determined and compared with their (111)In-labelled counterparts. METHODS: A monomeric (E-c(RGDfK)), a dimeric (E-[c(RGDfK)](2)) and a tetrameric (E{E[c(RGDfK)](2)}(2)) RGD peptide were synthesised, conjugated with DOTA and radiolabelled with (68)Ga. In vitro α(v)β(3)-binding characteristics were determined in a competitive binding assay. In vivo α(v)β(3)-targeting characteristics of the compounds were assessed in mice with subcutaneously growing SK-RC-52 xenografts. In addition, microPET images were acquired using a microPET/CT scanner. RESULTS: The IC(50) values for the Ga(III)-labelled DOTA-E-c(RGDfK), DOTA-E-[c(RGDfK)](2) and DOTA-E{E[c(RGDfK)](2)}(2) were 23.9 ± 1.22, 8.99 ± 1.20 and 1.74 ± 1.18 nM, respectively, and were similar to those of the In(III)-labelled mono-, di- and tetrameric RGD peptides (26.6 ± 1.15, 3.34 ± 1.16 and 1.80 ± 1.37 nM, respectively). At 2 h post-injection, tumour uptake of the (68)Ga-labelled mono-, di- and tetrameric RGD peptides (3.30 ± 0.30, 5.24 ± 0.27 and 7.11 ± 0.67%ID/g, respectively) was comparable to that of their (111)In-labelled counterparts (2.70 ± 0.29, 5.61 ± 0.85 and 7.32 ± 2.45%ID/g, respectively). PET scans were in line with the biodistribution data. On all PET scans, the tumour could be clearly visualised. CONCLUSION: The integrin affinity and the tumour uptake followed the order of DOTA-tetramer > DOTA-dimer > DOTA-monomer. The (68)Ga-labelled tetrameric RGD peptide has excellent characteristics for imaging of α(v)β(3) expression with PET. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s00259-010-1615-x) contains supplementary material, which is available to authorized users. Springer-Verlag 2010-09-21 2011 /pmc/articles/PMC3005123/ /pubmed/20857099 http://dx.doi.org/10.1007/s00259-010-1615-x Text en © The Author(s) 2010 https://creativecommons.org/licenses/by-nc/4.0/ This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.
spellingShingle Original Article
Dijkgraaf, Ingrid
Yim, Cheng-Bin
Franssen, Gerben M.
Schuit, Robert C.
Luurtsema, Gert
Liu, Shuang
Oyen, Wim J. G.
Boerman, Otto C.
PET imaging of α(v)β(3) integrin expression in tumours with (68)Ga-labelled mono-, di- and tetrameric RGD peptides
title PET imaging of α(v)β(3) integrin expression in tumours with (68)Ga-labelled mono-, di- and tetrameric RGD peptides
title_full PET imaging of α(v)β(3) integrin expression in tumours with (68)Ga-labelled mono-, di- and tetrameric RGD peptides
title_fullStr PET imaging of α(v)β(3) integrin expression in tumours with (68)Ga-labelled mono-, di- and tetrameric RGD peptides
title_full_unstemmed PET imaging of α(v)β(3) integrin expression in tumours with (68)Ga-labelled mono-, di- and tetrameric RGD peptides
title_short PET imaging of α(v)β(3) integrin expression in tumours with (68)Ga-labelled mono-, di- and tetrameric RGD peptides
title_sort pet imaging of α(v)β(3) integrin expression in tumours with (68)ga-labelled mono-, di- and tetrameric rgd peptides
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3005123/
https://www.ncbi.nlm.nih.gov/pubmed/20857099
http://dx.doi.org/10.1007/s00259-010-1615-x
work_keys_str_mv AT dijkgraafingrid petimagingofavb3integrinexpressionintumourswith68galabelledmonodiandtetramericrgdpeptides
AT yimchengbin petimagingofavb3integrinexpressionintumourswith68galabelledmonodiandtetramericrgdpeptides
AT franssengerbenm petimagingofavb3integrinexpressionintumourswith68galabelledmonodiandtetramericrgdpeptides
AT schuitrobertc petimagingofavb3integrinexpressionintumourswith68galabelledmonodiandtetramericrgdpeptides
AT luurtsemagert petimagingofavb3integrinexpressionintumourswith68galabelledmonodiandtetramericrgdpeptides
AT liushuang petimagingofavb3integrinexpressionintumourswith68galabelledmonodiandtetramericrgdpeptides
AT oyenwimjg petimagingofavb3integrinexpressionintumourswith68galabelledmonodiandtetramericrgdpeptides
AT boermanottoc petimagingofavb3integrinexpressionintumourswith68galabelledmonodiandtetramericrgdpeptides